先锋研究者对技术采用的局部影响：来自新型抗癌药物的证据
THE LOCAL INFLUENCE OF PIONEER INVESTIGATORS ON TECHNOLOGY ADOPTION: EVIDENCE FROM NEW CANCER DRUGS.
作者信息
Agha Leila, Molitor David
机构信息
Dartmouth College and NBER.
University of Illinois and NBER.
出版信息
Rev Econ Stat. 2018 Mar;100(1):29-44. doi: 10.1162/REST_a_00670. Epub 2018 Mar 2.
Abstract
Local opinion leaders may play a key role in easing information frictions associated with technology adoption. This paper analyzes the influence of physician investigators who lead clinical trials for new cancer drugs. By comparing diffusion patterns across 21 new cancer drugs, we separate correlated regional demand for new technology from information spillovers. Patients in the lead investigator's region are initially 36% more likely to receive the new drug, but utilization converges within four years. We also find that superstar physician authors, measured by trial role or citation history, have broader influence than less prominent authors.
摘要
当地意见领袖可能在缓解与技术采用相关的信息摩擦方面发挥关键作用。本文分析了领导新癌症药物临床试验的医师研究者的影响。通过比较21种新癌症药物的扩散模式，我们将新技术的相关区域需求与信息溢出区分开来。主要研究者所在地区的患者最初接受新药的可能性要高出36%，但四年内使用率趋于一致。我们还发现，以试验角色或引用记录衡量的超级明星医师作者比不太知名的作者具有更广泛的影响力。
相似文献
1
THE LOCAL INFLUENCE OF PIONEER INVESTIGATORS ON TECHNOLOGY ADOPTION: EVIDENCE FROM NEW CANCER DRUGS.先锋研究者对技术采用的局部影响：来自新型抗癌药物的证据
Rev Econ Stat. 2018 Mar;100(1):29-44. doi: 10.1162/REST_a_00670. Epub 2018 Mar 2.
2
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.阿法替尼单药或联合长春瑞滨与曲妥珠单抗、拉帕替尼或两者治疗后出现进展性脑转移的 HER2 阳性乳腺癌患者的研究者选择治疗方案：一项随机、开放标签、多中心、Ⅱ期临床试验（LUX-Breast 3）。
Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17.
3
Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?3期临床试验中的临床资助支付方式会影响后续临床研究者的处方行为吗？
Dis Manag. 2004 Spring;7(1):77-87. doi: 10.1089/109350704322919014.
4
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明：临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
5
When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies.何时以及如何评估快速变化的技术：四种通用技术在医学应用方面的比较研究
Health Technol Assess. 1997;1(14):i-vi, 1-149.
7
Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.用于肝脏疾病的超声剪切波弹性成像：对该领域众多参与者的批判性评估
Ultraschall Med. 2016 Feb;37(1):1-5. doi: 10.1055/s-0035-1567037. Epub 2016 Feb 12.
8
Hospital quality of care: does information technology matter? The relationship between information technology adoption and quality of care.医院医疗质量：信息技术重要吗？信息技术应用与医疗质量之间的关系。
Health Care Manage Rev. 2008 Jan-Mar;33(1):51-9. doi: 10.1097/01.HMR.0000304497.89684.36.
9
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.一项III期研究，旨在评估替西罗莫司与研究者选择的疗法相比，用于治疗复发或难治性套细胞淋巴瘤的疗效。
J Clin Oncol. 2009 Aug 10;27(23):3822-9. doi: 10.1200/JCO.2008.20.7977. Epub 2009 Jul 6.
10
[Participation to international registration trials--from the investigator's standpoint].[从研究者角度看参与国际注册试验]
Gan To Kagaku Ryoho. 2007 Feb;34(2):297-300.
引用本文的文献
1
Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer.试验中的获益能否预测转移性去势抵抗性前列腺癌在现实世界中的疗效？
JNCI Cancer Spectr. 2025 Mar 3;9(2). doi: 10.1093/jncics/pkaf018.
2
REPRESENTATION AND EXTRAPOLATION: EVIDENCE FROM CLINICAL TRIALS.代表性与外推法：来自临床试验的证据。
Q J Econ. 2024 Feb;139(1):575-635. doi: 10.1093/qje/qjad036. Epub 2023 Sep 5.
3
Geographic disparity in the distribution of cancer clinical trials in the United States and the associated factors.美国癌症临床试验分布的地域差异及相关因素。
J Manag Care Spec Pharm. 2024 Apr;30(4):376-385. doi: 10.18553/jmcp.2024.30.4.376.
4
The diffusion of health care fraud: A bipartite network analysis.医疗保健欺诈的传播：一个双重网络分析。
Soc Sci Med. 2023 Jun;327:115927. doi: 10.1016/j.socscimed.2023.115927. Epub 2023 Apr 28.
5
Drug Diffusion Through Peer Networks: The Influence of Industry Payments.药物在同行网络中的传播：行业支付的影响。
Am Econ J Econ Policy. 2022 May;14(2):1-33. doi: 10.1257/pol.20200044.
6
Dynamics of Health Technology Diffusion in the Integrated Care System (DHTDICS): A Development and Validation Study in China.整合照护系统中的健康技术扩散动态（DHTDICS）：一项在中国进行的开发与验证研究
Risk Manag Healthc Policy. 2021 Jan 27;14:331-344. doi: 10.2147/RMHP.S293144. eCollection 2021.
7
Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.外科医生和肿瘤内科医生同行网络对 21 基因乳腺癌复发评分检测的应用的影响。
Cancer Med. 2021 Feb;10(4):1253-1263. doi: 10.1002/cam4.3720. Epub 2021 Jan 16.
8
Association of Quetiapine Overuse Letters With Prescribing by Physician Peers of Targeted Recipients: A Secondary Analysis of a Randomized Clinical Trial.喹硫平过度使用信件与目标收件人医生同行处方的关联：一项随机临床试验的二次分析
JAMA Psychiatry. 2019 Oct 1;76(10):1094-1095. doi: 10.1001/jamapsychiatry.2019.1418.
9
Patient Characteristics Associated with Receipt of Prescription Weight-Management Medications Among Veterans Participating in MOVE!参与 MOVE! 的退伍军人中，与开具处方体重管理药物相关的患者特征
Obesity (Silver Spring). 2019 Jul;27(7):1168-1176. doi: 10.1002/oby.22503. Epub 2019 May 15.
本文引用的文献
1
Learning, Misallocation, and Technology Adoption: Evidence from New Malaria Therapy in Tanzania.学习、资源错配与技术采用：来自坦桑尼亚新型疟疾治疗方法的证据
Rev Econ Stud. 2014;81(4):1331-1365. doi: 10.1093/restud/rdu020.
2
Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.晚期卵巢癌治疗指南依从性的空间分析及种族和社会经济地位的影响。
Gynecol Oncol. 2014 Jul;134(1):60-7. doi: 10.1016/j.ygyno.2014.03.561. Epub 2014 Mar 25.
3
The diffusion of microfinance.小额信贷的传播。
Science. 2013 Jul 26;341(6144):1236498. doi: 10.1126/science.1236498.
4
Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population.医疗保险人群中上皮性卵巢癌女性的癌症定向手术和死亡率的区域差异。
Cancer. 2010 Oct 15;116(20):4840-8. doi: 10.1002/cncr.25242.
5
Income, insurance, and technology: why does health spending outpace economic growth?收入、保险和技术：为何医疗支出增速快于经济增长？
Health Aff (Millwood). 2009 Sep-Oct;28(5):1276-84. doi: 10.1377/hlthaff.28.5.1276.
6
Limits on Medicare's ability to control rising spending on cancer drugs.医疗保险在控制癌症药物支出不断上涨方面的能力限制。
N Engl J Med. 2009 Feb 5;360(6):626-33. doi: 10.1056/NEJMhpr0807774. Epub 2009 Jan 27.
7
PRODUCTIVITY SPILLOVERS IN HEALTHCARE: EVIDENCE FROM THE TREATMENT OF HEART ATTACKS.医疗保健中的生产率溢出效应：来自心脏病治疗的证据
J Polit Econ. 2007;115:103-140. doi: 10.1086/512249.
8
Geographic access to cancer care in the U.S.美国癌症护理的地理可及性
Cancer. 2008 Feb 15;112(4):909-18. doi: 10.1002/cncr.23229.
9
The meaning of author order in medical research.医学研究中作者排序的意义。
J Investig Med. 2007 May;55(4):174-80. doi: 10.2310/6650.2007.06044.
10
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.替西罗莫司、干扰素α或两者联合用于晚期肾细胞癌。
N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.
Zotero 插件